Brain gene infusion tested for Parkinson's
NCT ID NCT01621581
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 32 times
Summary
This early-stage study tested a gene therapy that delivers a protective protein called GDNF directly to the brain in 25 people with advanced Parkinson's disease. The goal was to see if it is safe and if it might help protect dopamine-producing brain cells. Participants received the treatment through a special infusion during surgery and were followed for up to 5 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.